No-Cost, No-Obligation Louisiana Pradaxa Lawsuit Review

Bookmark and Share

Louisiana Pradaxa and Actos Lawsuits

Louisiana Pradaxa Lawsuits Filed for Internal Bleeding and Heart Attacks - Attorneys Handling Louisiana Pradaxa Lawsuits Offer No-Cost, No-Obligation Pradaxa Case Review

Pradaxa Health Problems

Pradaxa (dabigatran etexilate mesylate), an anti-coagulant drug, has been found to cause serious and even fatal bleeding incidents. Pradaxa is widely prescribed to reduce the risk of stroke in patients with atrial fibrillation. Atrial fibrillation (AFib) is the most commonly diagnosed heart arrhythmia; over 2.6 million Americans are affected by this life-threatening condition. Pradaxa, a direct thrombin inhibiting drug, prevents stroke by reducing the body's ability to form blood clots. A 2011 FDA Safety Communication stated that Pradaxa may be more likely to cause life threatening bleeding than other drugs used for this purpose. People who have lost a family member to fatal Pradaxa bleeding are working with Pradaxa internal bleeding lawyers in order to seek compensation for medical bills and the pain and suffering associated with their loss.

This website offers comprehensive information about Pradaxa heart attack and internal bleeding risks and Louisiana Pradaxa lawsuits, including why Pradaxa is prescribed to people with irregular heartbeat, what makes Pradaxa dangerous, where to find information about the Pradaxa internal bleeding FDA warning, what you might expect from a Pradaxa heart attack lawsuit or Pradaxa internal bleeding lawsuit in Louisiana, and how to contact a Pradaxa lawyer handling Louisiana lawsuits.

Louisiana Pradaxa Lawsuits

Louisiana Pradaxa Lawsuits

The undisclosed increased risk of a Pradaxa heart attack or death from Pradaxa internal bleeding has resulted in numerous Louisiana Praxa lawsuits being filed. These lawsuits allege that the maker of Pradaxa did not provide adequate warnings to Pradaxa users regarding the increased risks. Our Louisiana Pradaxa lawsuit information page will answer many of your questions as well as provide a no-cost, no-obligation Louisiana Pradaxa lawsuit case review.

Pradaxa Lawsuit FAQs

Louisiana Pradaxa Lawsuit FAQs

This section answers questions about how Pradaxa is used decrease the risk of stroke in people with atrial fibrillation, what the known risks are with Pradaxa internal bleeding, who can file a Louisiana Pradaxa lawsuit and the steps to do so, and answers to other Pradaxa lawsuit questions you may have.

Pradaxa Heart Attack

Pradaxa Internal Bleeding Risk

Pradaxa is a blood thinning drug prescribed to patients with a heart arrhythmia in order to prevent the development of dangerous blood clots that could result in stroke. Post-market reporting and the development of initial Pradaxa internal bleeding death lawsuits shows that Pradaxa may be more dangerous than researchers initially believed. This section offers detailed information about the associated danger of Pradaxa internal bleeding. The risk of Pradaxa heart attack (myocardial infarction) has been identified in studies published by prominent medical journals and is now under investigation at the FDA. The Pradaxa heart attack risk has been deemed so severe that a prominent medical director has advised using alternative medications.

Pradaxa FDA Warning

Pradaxa FDA Warning
The FDA issued a Safety Communication on December 7, 2011, on the use of Pradaxa to prevent stroke in patients with atrial fibrillation. While the risk of serious bleeding is known to be a side effect of any blood thinner, post market reports indicate that Pradaxa may cause serious bleeding more often than expected. The FDA is now conducting further research to determine the full extent of Pradaxa's dangers. Read here to learn what the Pradaxa FDA warning says, why the FDA is conducting more research and who is most at risk for developing Pradaxa internal bleeding.